Vaxart, Inc.

VXRT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Revenue $5.8M $9.3M $24.6M $68.7M $33.6M $20.4M $14.8M $35.0M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $12.4M $26.3M $19.8M $17.5M $19.9M $24.1M $17.8M $26.1M
SG&A Expense $3.5M $8.0M $9.4M $10.2M $18.0M $9.4M $5.4M $6.2M
Operating Income $-10.0M $-25.2M $-19.5M $-11.5M $-22.1M $-22.9M $-9.8M $-1.2M
Operating Margin -171.5% -271.0% -79.3% -16.7% -65.8% -112.3% -65.8% -3.4%
Interest Expense $3.0M $210.0K
Pretax Income $-9.6M $-25.4M $-19.2M $-11.3M $-8.8M $-19.7M $-9.5M $-887.0K
Income Tax Expense $300.0K $-100.0K $-300.0K $100.0K $-500.0K $-2.0M $-1.8M
Net Income $-9.6M $-25.4M $-19.1M $-11.0M $-8.9M $-19.2M $-4.5M $878.0K
Net Margin -164.1% -273.1% -77.6% -16.0% -26.5% -94.1% -30.5% 2.5%
EPS (Basic) $-91.65 $-0.66 $-0.54 $-0.35 $-0.32 $-0.85 $-0.18 $0.02
EPS (Diluted) $-91.65 $-0.66 $-0.54 $-0.35 $-0.32 $-0.85 $-0.18 $0.02
Shares Outstanding (Basic) 38.6M 38.6M 35.4M 31.3M 28.2M 22.7M 42.3M 44.3M
Shares Outstanding (Diluted) 38.6M 38.6M 35.4M 31.3M 28.2M 22.7M 42.3M 44.4M
Dividends Per Share
← Newer Page 2 of 3 Older →